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Background-—Most studies of risk assessment or stratiﬁcation in patients with myocardial infarction (MI) have been static and fail
to account for the evolving nature of clinical events and care processes. We sought to identify predictors of mortality,
cardiovascular death or nonfatal MI, and cardiovascular death or nonfatal heart failure (HF) over time in patients with HF, left
ventricular systolic dysfunction, or both post-MI.
Methods and Results-—Using data from the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial, we developed models to
estimate the association between patient characteristics and the likelihood of experiencing an event from the time of a follow-up
visit until the next visit. The intervals are: hospital arrival to discharge or 14 days, whichever occurs ﬁrst; hospital discharge to
30 days; 30 days to 6 months; and 6 months to 3 years. Models were also developed to predict the entire 3-year follow-up period
using baseline information. Multivariable Cox proportional hazards modeling was used throughout with Wald chi-squares as the
comparator of strength for each predictor. For the baseline model of overall mortality, the 3 strongest predictors were age
(adjusted hazard ratio [HR], 1.35; 95% CI, 1.28–1.42; P<0.0001), baseline heart rate (adjusted HR, 1.17; 95% CI, 1.14–1.21;
P<0.0001), and creatinine clearance (≤100 mL/min; adjusted HR, 0.86; 95% CI, 0.84–0.89; P<0.0001). According to the
integrated discrimination improvement (IDI) and net reclassiﬁcation improvement (NRI) indices, the updated model had signiﬁcant
improvement over the model with baseline covariates only in all follow-up periods and with all outcomes.
Conclusions-—Patient information assessed closest to the time of the outcome was more valuable in predicting death when
compared with information obtained at the time of the index hospitalization. Using updated patient information improves prognosis
over using only the information available at the time of the index event. ( J Am Heart Assoc. 2016;5:e003045 doi: 10.1161/
JAHA.115.003045)
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P atients with myocardial infarction (MI) complicated byheart failure (HF), left ventricular (LV) systolic dysfunc-
tion (LVSD), or both face a higher risk of in-hospital and
postdischarge fatal and nonfatal ischemic and arrhythmic
events than patients without these complications.1–5
Although the management of patients with MI is dynamic,
most studies of risk assessment or stratiﬁcation in these
patients have been static, derived only from data collected at
admission6–9 or discharge,10 and have failed to account for
the evolving nature of clinical measures and care processes.
Updated stratiﬁcation of risk at follow-up visits may allow
clinicians to target those more likely to experience adverse
events. This would allow clinicians to tailor intensity of
treatment to severity of illness and may result in cost savings
by avoiding unnecessary treatments in lower-risk patients.
Using data from the VALsartan In Acute myocardial
iNfarcTion (VALIANT) trial, we sought to identify predictors of
in-hospital, 30-day, 6-month, and 3-year mortality; and cardio-
vascular death or MI, and cardiovascular death or HF in
patients with HF, LVSD, or both post-MI. In particular, we
examined whether baseline risk markers lost relevance over
time with current physical ﬁndings supplanting these factors
as the most potent predictors of risk in the next time interval.
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Methods
A detailed description of the VALIANT trial has been
published.11 In brief, 14 703 patents with MI complicated
by HF, LVSD, or both were randomized a median of 4.9 days
post-MI. VALIANT was a double-blind, randomized, controlled
trial of treatment with valsartan, captopril, or both in patients
with acute MI complicated by HF, LVSD, or both. Patients
were enrolled at 931 hospitals in 24 countries between
December 1998 and June 2001. Median duration of follow-up
was 24.7 months. We analyzed data collected at discharge (or
at 14 days if the patient was still hospitalized), 30 days15,
and 180 days15.
An institutional review board or ethics committee at each
participating site approved the VALIANT trial protocol, and all
patients provided informed consent.
Statistical Analysis
Baseline data were nearly complete. There were very few
missing observations for any one variable. Across the baseline
parameters used, this ranged from0% to 3%. In the postbaseline
factors, no variable exhibited more than 10% missingness.
Markov chain Monte Carlo imputation was used to complete
the data set for modeling. Multiple imputation methodology
was applied to the mortality model as well as single imputation,
and changes in estimates were negligible when comparing the
2 methods; therefore, only single imputation was used in the
analyses presented. A series of models were developed to
predict outcomes as follows: data collected before randomiza-
tion into the VALIANT study (baseline data) were used to predict
to 3 years; baseline data were used to predict outcomes to
discharge from the index hospitalization; baseline through
hospital discharge data were used to predict outcomes to
30 days; baseline through 30 days data were used to predict
outcomes to 6 months; and baseline through 6 months data
were used to predict outcomes to 3 years. These prediction
intervals approximate the information a physician has at the
time of a follow-up visit. The models were developed to see how
well this information can predict status post-visit until the
patient returns for a subsequent visit. Three endpoints were
considered in this modeling process—all-cause mortality,
cardiovascular death or HF resulting in hospitalization, and
cardiovascular death or MI. Cardiovascular death was deﬁned
as any death adjudicated as cardiovascular, including the
following categories: sudden death; presumed cardiovascular
death; fatal heart failure; fatal reinfarction; cardiovascular-
procedure–related death; fatal stroke; and death from other
cardiovascular death.11,12
Forty-six baseline candidate variables, chosen based on
clinical input, were considered. These variables included
medical history, events post-qualifying MI and before
randomization, geographical region, vital signs, randomized
treatment, and creatinine levels at randomization. For the
models starting after hospital discharge, the following addi-
tional variables were considered during follow-up visits: heart
rate; blood pressure; hospitalization for HF; cardiac arrest; MI;
unstable angina; stroke; New York Heart Association (NYHA)
class; use of an automatic implantable cardioverter deﬁbril-
lator; percutaneous coronary intervention (PCI); coronary
artery bypass graft (CABG) surgery; and nonrandomized use
of angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers. If a nonfatal event or treatment occurred
during any previous follow-up period, it was included as a
covariate in subsequent models. For heart rate, blood
pressure, and NYHA classiﬁcation, only measures from the
visits preceding the follow-up period of interest and at
baseline were used.
Multivariable Cox proportional hazards modeling was used
throughout. The assumptions of linearity for each model were
assessed for continuously distributed candidate variables using
restricted cubic splines. In all cases, either contiguous linear
splines or truncation of the variable were deemed adequate to
meet assumptions of linearity. When possible, the same knot
point for linear splines and truncations was used across all
models to make interpretation easier. Backward, forward, and
step-wise variable selections were performed using a P value of
0.05 for inclusion and retention. If a difference existed between
the resulting models, the likelihood ratio tests and Akaike’s
information criterion were compared to determine the ﬁnal
model. All models were regenerated using the baseline
characteristics only to examine improvement in discrimination
and calibration with the inclusion of time-sensitive variables.
The relative importance of variables within each model was
ranked according to the model Wald chi-squares.
Discrimination was described with the c-index, integrated
discrimination improvement (IDI) index, and net reclassiﬁca-
tion improvement (NRI) index.13,14 The horizon of follow-up for
all measures was the length of the follow-up period. Events
occurring after the follow-up period were considered non-
events for the period of interest. Probability curves were
created for the last 3 follow-up periods.15 These curves
illustrate the distribution of predicted probabilities for models
with and without the time-sensitive factors. They also include
deciles of actual versus predicted risk as a measure of the
calibration of each model. These curves allow the reader to
note the distribution of risk across the population, if and
where the distribution is different for the 2 models, and how
well the models agree with the actual distribution of risk.
The NRI index evaluates the movement between risk
categories based on the predicted probabilities of 2 models.
Four risk categories were chosen approximately at the
quartiles. The better of 2 models would predict higher event
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without. Therefore, movement of events into a higher-risk
category and nonevents into a lower-risk category is consid-
ered improvement. Likewise, movement of events into a
lower-risk category and nonevents into a higher-risk category
is considered worsening of classiﬁcation. The NRI index is the
sum of the percent improvement, for events and nonevents,
achieved by using the model with time-updated variables
versus the model with baseline covariates only. Those lost to
follow-up before the speciﬁed time horizon were handled
using Kaplan–Meier estimates of the expected number of
events and nonevents (“prospective NRI”).13
NRI ¼ ðaþ bÞevents þ ðb aÞnonevents
a = proportion in higher-risk category based on predicted
values from a model using time-updated variables rather than
a model using baseline variables only. b = proportion in
lower-risk category based on predicted values from a model
using time-updated variables rather than a model using
baseline variables only.
The IDI index is the difference in discrimination slopes
under 2 models where the discrimination slope is the
difference in the average predicted probabilities for events
and nonevents. It can be interpreted as the percent improve-
ment in discrimination attained by using the time-updated
model over the model with baseline covariates only.
IDI ¼ c d
c = (mean predicted probability in patients with eventsmean
predicted probability in patients without events) in the time-
updated model. d = (mean predicted probability in patients
with eventsmean predicted probability in patients without
events) in the baseline model.
All models were developed using SAS software (versions
8.2 and 9.1; SAS Institute Inc., Cary, NC).
Results
Mortality Model
The main predictors of mortality at the different time points
are shown in Table 1. For overall mortality, the 5 strongest
predictors were age (adjusted hazard ratio [HR], 1.35 per
10 years; 95% CI, 1.28–1.42; P<0.0001), baseline heart rate
(adjusted HR, 1.17 per 10 beats/min; 95% CI, 1.14–1.21;
P<0.0001), creatinine clearance (≤100 mL/min; adjusted HR,
0.86 per 10 units; 95% CI, 0.84–0.89; P<0.0001), new onset
diabetes (adjusted HR, 1.41; 95% CI, 1.30–1.52; P<0.0001),
and MI before the qualifying MI (adjusted HR, 1.40; 95% CI,
1.28–1.52; P<0.0001). The same factors were the 5 most
signiﬁcant for the composite outcome of cardiovascular death
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Killip class was ranked among the highest 5 and creatinine
clearance was not (Table 3). When evaluating predictors of
survival from events occurring during the index hospitalization
only, more baseline measurements become important and the
history variables less so. Weight and blood pressure now join
the ranks of heart rate and creatinine clearance as top 5
predictors. The 3 sets of models for events occurring after
discharge from the index hospitalization now include updated
events, such as new occurrence of HF, MI, stroke, or CABG
surgery in the top 5 predictors list. Table 4 shows all factors
chosen for the models as well as their relative ranks.
Comparison of Baseline With Time-Sensitive
Models
Inclusion of time-sensitive factors in mortality models had the
greatest effect on the acute model (c-index=0.77–0.81; IDI
index=4.9%; NRI index=22.3% for hospital discharge to
30 days; Table 5). Overall risk of dying between discharge
and 30 days was 2.2%. Models of 30-day to 6-month and 6-
month to 3-year mortality showed improvements in c-indices
of 0.02 and 0.02, IDI indices of 2.2% and 3.2%, and NRI
indices of 7.3% and 6.8% (Table 5).
When comparing 2 models, one would prefer to have a
lower prediction in the patients without the event and a higher
prediction in those with the event. As illustrated in the Figure,
one would expect the values for those without the event to go
down (ie, lower predicted values with the updated information)
and the values for those with the event to go up (ie, higher
predicted values with the updated information). Between the
25th and 75th percentiles of the change in predicted values,
the 2 models were comparable in their predictions of patients
who survived during each time interval (Figure). However, more
change was observed in predictions in the patients who
subsequently died, with the updated models assigning those
who subsequently died a higher probability of the event than
that assigned by the baseline model.
Changes in c-indices were less pronounced for the models
of composite outcomes (Table 5). According to the IDI and
NRI indices, the updated model had signiﬁcant improvement
over the model with baseline covariates only in all follow-up
periods and with all outcomes (Table 5).
Discussion
Although assessment of risk at the time of an acute event is
interesting and important, the approach seems insensitive
when more information on clinical status is collected in the
hospital and during subsequent outpatient clinic visits. The
dynamic, time-updated approach more closely simulates
clinical practice in which providers assess patient status
and adjust treatment and expectations as a function of the
trajectory of the disease process.
Our ﬁndings demonstrate the need to move from risk
modeling based on a ﬁxed time point to more-dynamic risk
modeling in which future outcomes are predicted with the most
relevant and time-updated data, including intervening changes
in clinical status between the initial and current evaluations.
Many of the baseline factors associated with outcomes to
3 years are also found to be important during the follow-up
periods. However, the relationship of these factors at baseline
weakens as time passes, and intervening events and current
clinical ﬁndings become much stronger predictors of outcomes
in the subsequent intervals. The period from discharge to
30 days is short, and thus the overall risk is low (FigureA). Most
patients had predicted risks around that for the overall group
(2.2% for mortality). The information updated at hospital
discharge mainly changed the distribution of risk for those at
high risk of an event. By 6 months of follow-up, updating the
clinical risk factors was associated with changes in risk to
3 years across the entire spectrum of risk.
It has been over 40 years since Killip ﬁrst described the
importance of the hemodynamic status after acute MI as a
predictor of mortality.16 Since then, numerous studies have
identiﬁed clinical signs of HF in the setting of MI as important
predictors of prognosis.3–5,8,17 However, the majority of these
predictors are baseline characteristics and infarct severity,18
and previous statistical approaches have not taken into
account the changes that occur in a patient’s health over time.
In addition, it has been shown that in patients with chronic HF,
risk of death is highest in the early phase after hospital
discharge (attributed to a hospitalization for an HF event) and
related to the duration and frequency of HF hospitalizations.19
Chang et al.20 showed that risk stratiﬁcation for patients
with non-ST-segment elevation (NSTE)-acute coronary syn-
dromes (ACS) should be updated over time to better estimate
the patient’s risk and provide information that might lead to
improved decision making. In that study, it was shown that
the methodological process of assessing risk at different time
points during the hospital stay was a feasible and reliable
strategy to guide the management of patients with NSTE-ACS.
Dynamic risk assessment models were also tested in over
6000 patients with ST-segment elevation MI.12 In that study,
factors not available at baseline, such as ST-segment
evolution and in-hospital complications, added prognostic
information. These results were applicable not only for
patients who received thrombolytic therapy, but also for
those who underwent primary PCI.
We were able to assess patient characteristics at different
time points, including in-hospital, short-, and long-term
periods, using almost 15 000 patients enrolled in the
VALIANT study, and we used the data from each time point
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baseline characteristics were not strongly associated with 30-
day, 6-month, and 3-year mortality after adjusting for these
same values measured closer to the latest time period. For
example, the most important predictive factors in the model
of mortality between hospital discharge and the 30-day
follow-up visit were variables captured at discharge and not at
baseline. Similarly, the most important factors for the model
































































































































































































































































































































































































































































































































































































































































































Figure. Box plots of the change in predicted risk of
mortality (predicted risk from the updated modelpre-
dicted risk from baseline characteristics only model).
Distributions of change in prediction are illustrated
separately for those who died and those who did not
within each of the last 3 follow-up intervals: (A) hospital
discharge to 30 days; (B) 30 days to 6 months; and (C)
6 months to 3 years.
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variables assessed at the 30-day visit and not baseline or
discharge characteristics. Finally, the most important vari-
ables in the model of mortality from 6 months to the 3-year
follow-up visit were those measured at the 6-month visit, such
as heart rate and NYHA class.
This was true not only for mortality, but also for the
cardiovascular death or HF and cardiovascular death or MI
models. This is the ﬁrst time that a dynamic assessment with 4
different time points including short- and long-term (3-year)
outcomes has been performed to better understand the
predictors of these clinical outcomes in patients with HF after
acute MI.
Analyses from the Worcester Heart Attack study showed a
decline in the incidence rates of HF complicating acute MI and
signiﬁcant improvements in in-hospital survival after acute MI
complicated by HF.1 These decreased rates of HF after acute
MI are likely attributed to the increasing use of preventive and
appropriate therapeutic strategies directed at patients at high
risk for developing HF. However, this trend was not observed
in the postdischarge 1-year survival. These ﬁndings highlight
the prognostic inﬂuence of HF after acute MI. The lack of
improvement over time in the long-term outcomes of these
patients may reﬂect the underuse or underdosing of effective
cardiac therapies available; poor patient compliance; or less
focus on characteristics that might predict worse outcomes,
other than baseline variables, that were important for the in-
hospital period. Therefore, there is a need to identify
modiﬁable long-term predictors for physicians to focus on in
order to intensify treatment and improve clinical outcomes.
Our study showed that there are several strong predictors of
outcomes that can be potentially modiﬁed or better con-
trolled, such as NYHA class, heart rate, creatinine clearance,
weight, and diabetes mellitus, that might inform future targets
for interventions. These risk markers might be modiﬁed in
beneﬁcial or detrimental ways; therefore, randomized trials
are needed to test further interventions in this population. All
available evidence indicates that the greatest absolute beneﬁt
for proven therapies is for those at the highest risk, and
identiﬁcation of a high-risk patient at a clinic visit may merit
special allocation of time to ensure that the best evidence-
based therapies are available and used. Time-updated risk
models may be used to identify populations in need of further
research in follow-up from acute events, to use in adjusting
for risk when comparing outcomes between centers in quality
exercises, or to create an opportunity for providers and health
systems to focus on the highest-risk populations to ensure
that they are treated with the highest standards.
Limitations
Not all of the clinical measures were available at both baseline
and follow-up. NYHA class could not be included in the
baseline models, creatinine clearance was measured only
when changes in the study drug titration occurred during the
follow-up period, and LV function was not measured in a
uniform manner at baseline and not at all during the follow-up
periods. Thus, assessing changes over time in these measures
was not possible. We did not have information about the
extent of coronary disease in all patients, which may have
been an important contributor to patient status. It is also
possible that other important factors were not captured in our
database. For example, biomarkers were not available for us
to model and our results may have been different had they
been known.
We did not examine all of the possible follow-up periods;
however, we felt that the time points evaluated were
representative of important clinic visits.
We used imputed data instead of complete case analyses.
If complete case results had been performed and different
results found, we cannot be sure that the imputed results
were less biased. The proportional hazards assumption may
have been violated in some models. Thus, the predictions are
averaged within each time interval rather than allowing for
changing risk within a time interval.
We also evaluated changes in patient status from one visit
to the next. We could have examined the changes from the
visit of interest to the last known follow-up and differing
results may have been noted. We were more interested in how
the information obtained at a clinic visit helps physicians
predict how the patient will do until the next important
milestone; therefore, the process chosen better ﬁts our goals.
Conclusions
We found that although baseline characteristics at the time of
MI are important in determining outcome, patient information
assessed over time provides a clearer view of patient status
and is a better predictor of long-term outcomes. In these
mortality models, it appears that the use of updated
information does more to upgrade predictions of events than
to downgrade predictions of nonevents. In addition, we
identiﬁed important predictors that are modiﬁable and could
be better controlled. Clinical care should focus on these to
improve the care of patients with HF after acute MI. Further
exploration of the dynamic process of evaluating factors
associated with outcomes over long periods of time is
needed.
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